Kiyose-shi

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Asthma2 trials
• Lung cancer2 trials
• Alzheimer disease1 trial
• Bronchiectasis1 trial
• COPD1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Recruiting3 trials
• Not yet recruiting2 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• AstraZeneca6 trials
• Biogen1 trial

Running trials

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07088926· Phase 2· AstraZeneca· Source

• Recruiting

  Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

  NCT06932263· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  NCT06878261· Phase 3· AstraZeneca· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· Phase 3· AstraZeneca· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  NCT06692738· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting
• Asthma1 recruiting
• Bronchiectasis1 recruiting
• COPD1 recruiting

Closed trials

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· AstraZeneca· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source